Skip to main content
. Author manuscript; available in PMC: 2015 Sep 2.
Published in final edited form as: Anticancer Res. 2010 Sep;30(9):3279–3289.

Figure 1.

Figure 1

A) Western blot for basal levels of Akt and phospho-Akt in six pancreatic cancer cell lines with loading equivalency confirmed by immunoblotting for actin, B) FACS analysis following treatment with gemcitabine (100 µM), paclitaxel (100 nM) or carboplatin (270 µM) for 24 hours in AsPC-1, MiaPaCa-2 and PANC-1 with measurement of the sub-G0 peak is used as a marker of apoptosis, C) Induction of apoptosis following paclitaxel treatment (100 nM) over 48 hours in AsPC-1, PANC-1 and MIA-PaCa-2, D) Western blot following the indicated times of treatment following gemcitabine (100 µM), paclitaxel (100 nM) or carboplatin (270 µM) in MiaPaCa-2 cells for total Akt, phospho-Akt (pSer473) or actin to show for equivalency of loading, E) Western blot following the 6 hrs treatment with gemcitabine (100 µM), paclitaxel (100 nM) or carboplatin (270 µM) in MiaPaCa-2, PANC-1 or AsPC-1 cells for total Akt or phospho-Akt (pSer473).